As of the latest Form 4 filed Jul 8, 2026.
What Enliven Therapeutics Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 36 most recent filings for ELVN.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-08 | 2026-07-06 | Kunkel Lori Anne Director | SSale | −5.89K | $50.84 | $299K | Yes (planned) | Form 4 ↗ |
| 2026-07-08 | 2026-07-06 | Kunkel Lori Anne, Director | SSale | −4.11K | $49.98 | $205K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC 10% owner | SSale | −46.8K | $45.00 | $2.10M | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC, 10% owner | SSale | −787K | $45.38 | $35.7M | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC, 10% owner | SSale | −1.48K | $45.00 | $66.5K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | ORBIMED ADVISORS LLC, 10% owner | SSale | −24.8K | $45.38 | $1.13M | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SSale | −1.24K | $44.75 | $55.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Hohl Benjamin, CHIEF FINANCIAL OFFICER | SSale | −3.40K | $43.86 | $149K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Hohl Benjamin, CHIEF FINANCIAL OFFICER | SSale | −1.38K | $42.79 | $59.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Hohl Benjamin, CHIEF FINANCIAL OFFICER | MExercise | +6.02K | $2.48 | $14.9K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −1.13K | $44.74 | $50.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −2.60K | $43.87 | $114K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −1.27K | $42.83 | $54.3K | Yes (planned) | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +5.00K | $2.48 | $12.4K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | ORBIMED ADVISORS LLC 10% owner | SSale | −272K | $45.02 | $12.3M | No | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | ORBIMED ADVISORS LLC, 10% owner | SSale | −9.09K | $45.02 | $409K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Kunkel Lori Anne Director | SSale | −354.00 | $35.82 | $12.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Kunkel Lori Anne, Director | SSale | −1.87K | $35.36 | $66.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Kunkel Lori Anne, Director | SSale | −7.78K | $34.28 | $267K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −223.00 | $41.21 | $9.19K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −1.30K | $40.25 | $52.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −3.48K | $39.53 | $137K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +5.00K | $2.48 | $12.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −2.44K | $48.06 | $117K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −2.42K | $47.39 | $115K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −140.00 | $45.81 | $6.41K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +5.00K | $2.48 | $12.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-27 | 2026-03-25 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −40.0K | $35.10 | $1.40M | Yes (planned) | Form 4 ↗ |
| 2026-03-27 | 2026-03-25 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +40.0K | $2.48 | $99.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −5.00K | $27.76 | $139K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +5.00K | $2.48 | $12.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-10 | Collins Helen Louise CHIEF MEDICAL OFFICER | SSale | −10.1K | $30.19 | $306K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-10 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +10.1K | $2.48 | $25.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Collins Helen Louise, CHIEF MEDICAL OFFICER | SSale | −29.9K | $30.02 | $897K | Yes (planned) | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Collins Helen Louise, CHIEF MEDICAL OFFICER | MExercise | +29.9K | $2.48 | $74.1K | Yes (planned) | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Hohl Benjamin CHIEF FINANCIAL OFFICER | SSale | −10.0K | $29.58 | $296K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ELVN’s full analysis or the market-wide insider trading feed. The tabs above jump to ELVN’s other SEC data.
Source: SEC Form 4 filings for ELVN, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.